Viewing Study NCT00113256

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:16 PM
Ignite Modification Date: 2026-01-03 @ 7:56 PM
Study NCT ID: NCT00113256
Status: TERMINATED
Last Update Posted: 2024-08-02
First Post: 2005-06-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Sponsor: Astex Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None rubitecan View
None Orathecin View
None 9-nitrocamptothecin View
None gemcitabine View
None Gemzar View
None pancreatic cancer View
None adenocarcinoma View
None RFS 2000 View